<p>Envestnet Portfolio Solutions Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在精准医学公司 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的持股减少了 80.6%。该机构投资者在本季度出售了 58,727 股后，持有该医疗研究公司 14,155 股股票。根据其最近的 SEC 文件，Envestnet Portfolio Solutions Inc. 在 Exact Sciences 的持股价值为 752,000 美元。</p>
<p>获取 <strong>Exact Sciences</strong> 的提醒：</p>
<ul>
<li>Myriad Genetics 通过遗传性癌症检测看到股票激增</li>
</ul>
<p>其他对冲基金和机构投资者也调整了对该公司的持股。Larson Financial Group LLC 在第一季度将其在 Exact Sciences 的持股增加了 2,804.8%。Larson Financial Group LLC 现在持有 610 股该医疗研究公司的股票，价值 26,000 美元，此前在该期间又购买了 589 股。国家养老金服务在第一季度将其在 Exact Sciences 的持股增加了 75.1%。国家养老金服务现在持有 681 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 292 股。SVB Wealth LLC 在第一季度获得了 Exact Sciences 的新头寸，价值 30,000 美元。Banque Cantonale Vaudoise 在第一季度获得了 Exact Sciences 的新股份，价值约 34,000 美元。最后，Mirae Asset Global Investments Co. Ltd. 在第一季度获得了 Exact Sciences 的新股份，价值 34,000 美元。机构投资者和对冲基金持有该公司 88.82% 的股票。</p>
<h2>Exact Sciences 的内部活动</h2>
<p>在相关消息中，董事 James Edward Doyle 于 10 月 9 日星期四出售了 2,000 股 Exact Sciences 股票。该股票以每股 60.00 美元的平均价格出售，总价值为 120,000.00 美元。出售后，该董事持有 57,962 股公司的股票，价值约 3,477,720 美元。此次交易使其持股减少了 3.34%。该交易已在与证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。目前，1.20% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
<p>EXAS 最近成为多份研究报告的主题。BTIG Research 将 Exact Sciences 的目标价格从 65.00 美元下调至 60.00 美元，并在 8 月 12 日的研究报告中对该股票给予了 “买入” 评级。Piper Sandler 将 Exact Sciences 的目标价格从 60.00 美元上调至 70.00 美元，并在 10 月 8 日的研究报告中给予该公司 “增持” 评级。Craig Hallum 将 Exact Sciences 的目标价格从 65.00 美元上调至 85.00 美元，并在 9 月 11 日的报告中给予该股票 “买入” 评级。Cowen 在 8 月 7 日的研究报告中重申了对 Exact Sciences 的 “买入” 评级。最后，Barclays 将 Exact Sciences 的目标价格从 55.00 美元上调至 65.00 美元，并在 10 月 2 日的研究报告中给予该股票 “增持” 评级。两位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价格为 69.19 美元。</p>
<p><strong>获取我们关于 Exact Sciences 的最新股票报告</strong></p>
<h2>Exact Sciences 股票表现</h2>
<ul>
<li>是时候购买这些 3 家提高收入指引的医疗公司了吗？</li>
</ul>
<p>EXAS 股票在星期二开盘价为 62.73 美元。该公司的市值为 118.8 亿美元，市盈率为 -11.55，市盈增长比率为 5.43，贝塔值为 1.24。该公司的流动比率为 2.89，速动比率为 2.56，债务与股本比率为 0.94。该公司的 50 日移动平均价格为 52.67 美元，200 日移动平均价格为 51.31 美元。Exact Sciences Corporation 的 1 年低点为 38.81 美元，1 年高点为 72.83 美元。</p>
<p>Exact Sciences (NASDAQ:EXAS - 获取免费报告) 最近于 8 月 6 日发布了季度收益数据。该医疗研究公司报告本季度每股收益为 0.22 美元，超出分析师一致预期的 -0.02 美元，超出幅度为 0.24 美元。该公司本季度的收入为 8.1109 亿美元，而分析师预期为 7.7443 亿美元。Exact Sciences 的净利润率为 -34.19%，股本回报率为 -1.75%。该公司的季度收入同比增长 16.0%。去年同期，该公司每股收益为 -0.09 美元。整体来看，研究分析师预测 Exact Sciences Corporation 本年度每股收益将为 -0.58 美元。</p>
<h2>Exact Sciences 公司简介</h2>
<p>(免费报告)</p>
<p>Exact Sciences Corporation 提供癌症筛查和诊断测试产品，业务遍及美国及国际市场。该公司提供 Cologuard，一种非侵入性的基于粪便的 DNA 筛查测试，用于检测与结直肠癌和癌前病变相关的 DNA 和血红蛋白生物标志物。它还提供 Oncotype DX 乳腺复发评分测试；Oncotype DX 乳腺 DCIS 评分测试；Oncotype DX 结肠复发评分测试；OncoExTra 测试，用于对晚期、转移性、难治性、复发或复发性癌症患者进行肿瘤分析；以及 Covid-19 测试服务。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Exact Sciences</li>
<li>如何计算股票利润</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>每月分红股票的利与弊</li>
<li>3 家高收益银行，适合投资者在下跌时购买</li>
<li>投资汽车股票</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
<p><strong>想看看其他对冲基金持有的 EXAS 吗？</strong> 访问 HoldingsChannel.com 获取 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw"/></p>
<p><em>这条即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在精密科学吗？</h2>
<p>在考虑精密科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而精密科学并不在名单上。</p>
<p>虽然精密科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

精密科学

<p>Envestnet Portfolio Solutions Inc. 在第二季度减少了对精密科学（NASDAQ:EXAS）80.6% 的持股，目前持有 14,155 股，价值 752,000 美元。其他机构投资者也调整了他们的持仓，Larson Financial Group 的持股增加了 2,804.8%。最近的分析师评级显示，EXAS 的共识目标价为 69.19 美元，开盘价为 62.73 美元。该公司报告的季度每股收益为 0.22 美元，超出预期，收入为 8.1109 亿美元，同比增长 16%</p>

<p>Envestnet Portfolio Solutions Inc. cut its holdings in Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 80.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,155 shares of the medical research company's stock after selling 58,727 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Exact Sciences were worth $752,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Envestnet Portfolio Solutions Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在精准医学公司 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的持股减少了 80.6%。该机构投资者在本季度出售了 58,727 股后，持有该医疗研究公司 14,155 股股票。根据其最近的 SEC 文件，Envestnet Portfolio Solutions Inc. 在 Exact Sciences 的持股价值为 752,000 美元。</p>
</div><p>Get <strong>Exact Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Exact Sciences</strong> 的提醒：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 通过遗传性癌症检测看到股票激增</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also modified their holdings of the company. Larson Financial Group LLC increased its holdings in shares of Exact Sciences by 2,804.8% in the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company's stock valued at $26,000 after purchasing an additional 589 shares during the period. National Pension Service lifted its holdings in Exact Sciences by 75.1% in the 1st quarter. National Pension Service now owns 681 shares of the medical research company's stock worth $29,000 after purchasing an additional 292 shares during the last quarter. SVB Wealth LLC acquired a new position in Exact Sciences during the 1st quarter worth $30,000. Banque Cantonale Vaudoise acquired a new stake in Exact Sciences in the 1st quarter valued at approximately $34,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Exact Sciences in the 1st quarter worth $34,000. Institutional investors and hedge funds own 88.82% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也调整了对该公司的持股。Larson Financial Group LLC 在第一季度将其在 Exact Sciences 的持股增加了 2,804.8%。Larson Financial Group LLC 现在持有 610 股该医疗研究公司的股票，价值 26,000 美元，此前在该期间又购买了 589 股。国家养老金服务在第一季度将其在 Exact Sciences 的持股增加了 75.1%。国家养老金服务现在持有 681 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 292 股。SVB Wealth LLC 在第一季度获得了 Exact Sciences 的新头寸，价值 30,000 美元。Banque Cantonale Vaudoise 在第一季度获得了 Exact Sciences 的新股份，价值约 34,000 美元。最后，Mirae Asset Global Investments Co. Ltd. 在第一季度获得了 Exact Sciences 的新股份，价值 34,000 美元。机构投资者和对冲基金持有该公司 88.82% 的股票。</p>
</div><h2>Insider Activity at Exact Sciences</h2>
<div class="lb-trans"><h2>Exact Sciences 的内部活动</h2>
</div><p>In related news, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director owned 57,962 shares of the company's stock, valued at approximately $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 James Edward Doyle 于 10 月 9 日星期四出售了 2,000 股 Exact Sciences 股票。该股票以每股 60.00 美元的平均价格出售，总价值为 120,000.00 美元。出售后，该董事持有 57,962 股公司的股票，价值约 3,477,720 美元。此次交易使其持股减少了 3.34%。该交易已在与证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。目前，1.20% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Hot Stocks Bought by Members of Congress: Follow the Money</li>
</ul>
<div class="lb-trans"><ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
</div><p>EXAS has been the topic of a number of recent research reports. BTIG Research reduced their target price on shares of Exact Sciences from $65.00 to $60.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, August 12th. Piper Sandler boosted their price target on shares of Exact Sciences from $60.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, October 8th. Craig Hallum raised their price objective on shares of Exact Sciences from $65.00 to $85.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, September 11th. Cowen reiterated a &#34;buy&#34; rating on shares of Exact Sciences in a research note on Thursday, August 7th. Finally, Barclays increased their price target on Exact Sciences from $55.00 to $65.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $69.19.</p>
<div class="lb-trans"><p>EXAS 最近成为多份研究报告的主题。BTIG Research 将 Exact Sciences 的目标价格从 65.00 美元下调至 60.00 美元，并在 8 月 12 日的研究报告中对该股票给予了 “买入” 评级。Piper Sandler 将 Exact Sciences 的目标价格从 60.00 美元上调至 70.00 美元，并在 10 月 8 日的研究报告中给予该公司 “增持” 评级。Craig Hallum 将 Exact Sciences 的目标价格从 65.00 美元上调至 85.00 美元，并在 9 月 11 日的报告中给予该股票 “买入” 评级。Cowen 在 8 月 7 日的研究报告中重申了对 Exact Sciences 的 “买入” 评级。最后，Barclays 将 Exact Sciences 的目标价格从 55.00 美元上调至 65.00 美元，并在 10 月 2 日的研究报告中给予该股票 “增持” 评级。两位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价格为 69.19 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Exact Sciences</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Exact Sciences 的最新股票报告</strong></p>
</div><h2>Exact Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Exact Sciences 股票表现</h2>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>是时候购买这些 3 家提高收入指引的医疗公司了吗？</li>
</ul>
</div><p>EXAS stock opened at $62.73 on Tuesday. The firm has a market cap of $11.88 billion, a PE ratio of -11.55, a P/E/G ratio of 5.43 and a beta of 1.24. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. The business's 50-day moving average price is $52.67 and its two-hundred day moving average price is $51.31. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $72.83.</p>
<div class="lb-trans"><p>EXAS 股票在星期二开盘价为 62.73 美元。该公司的市值为 118.8 亿美元，市盈率为 -11.55，市盈增长比率为 5.43，贝塔值为 1.24。该公司的流动比率为 2.89，速动比率为 2.56，债务与股本比率为 0.94。该公司的 50 日移动平均价格为 52.67 美元，200 日移动平均价格为 51.31 美元。Exact Sciences Corporation 的 1 年低点为 38.81 美元，1 年高点为 72.83 美元。</p>
</div><p>Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.24. The business had revenue of $811.09 million for the quarter, compared to analyst estimates of $774.43 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm's quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the business posted ($0.09) earnings per share. As a group, research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>Exact Sciences (NASDAQ:EXAS - 获取免费报告) 最近于 8 月 6 日发布了季度收益数据。该医疗研究公司报告本季度每股收益为 0.22 美元，超出分析师一致预期的 -0.02 美元，超出幅度为 0.24 美元。该公司本季度的收入为 8.1109 亿美元，而分析师预期为 7.7443 亿美元。Exact Sciences 的净利润率为 -34.19%，股本回报率为 -1.75%。该公司的季度收入同比增长 16.0%。去年同期，该公司每股收益为 -0.09 美元。整体来看，研究分析师预测 Exact Sciences Corporation 本年度每股收益将为 -0.58 美元。</p>
</div><h2>Exact Sciences Profile</h2>
<div class="lb-trans"><h2>Exact Sciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.</p>
<div class="lb-trans"><p>Exact Sciences Corporation 提供癌症筛查和诊断测试产品，业务遍及美国及国际市场。该公司提供 Cologuard，一种非侵入性的基于粪便的 DNA 筛查测试，用于检测与结直肠癌和癌前病变相关的 DNA 和血红蛋白生物标志物。它还提供 Oncotype DX 乳腺复发评分测试；Oncotype DX 乳腺 DCIS 评分测试；Oncotype DX 结肠复发评分测试；OncoExTra 测试，用于对晚期、转移性、难治性、复发或复发性癌症患者进行肿瘤分析；以及 Covid-19 测试服务。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Exact Sciences</li>
<li>How to Calculate Stock Profit</li>
<li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>3 High-Yield Banks for Investors to Buy on the Dip</li>
<li>Investing In Automotive Stocks</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Exact Sciences</li>
<li>如何计算股票利润</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>每月分红股票的利与弊</li>
<li>3 家高收益银行，适合投资者在下跌时购买</li>
<li>投资汽车股票</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EXAS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 EXAS 吗？</strong> 访问 HoldingsChannel.com 获取 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXAS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Exact Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在精密科学吗？</h2>
</div><p>Before you consider Exact Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑精密科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而精密科学并不在名单上。</p>
</div><p>While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然精密科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Envestnet Portfolio Solutions Inc.减少了其在精密科学公司（Exact Sciences Corporation）$EXAS 的股票头寸